Fig. 2From: Long-term and acute safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) in juvenile and adult dogsMean milbemycin A4 5-oxime plasma concentrations at 24 h post-dosing in the adult and juvenile target animal safety studies following 1, 3 or 5X the recommended dose for seven and nine dose cycles, respectivelyBack to article page